美国Geron
Geron公司总部设在加州的Menlo Park Geron的研究人员正在研究这些干细胞能否帮助老鼠受损的心脏恢复健康

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. We are advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. We are also the world leader in the development of human embryonic stem cell-based therapeutics. We have received FDA clearance to begin the world's first human clinical trial of a hESC-based therapy: GRNOPC1 for acute spinal cord injury.

Incorporated in the state of Delaware in 1990, Geron has been in business since 1992. Our headquarters and main facilities are located in Menlo Park, California. Geron Bio-Med Limited is our wholly-owned subsidiary located in Edinburgh, Scotland. TA Therapeutics, Limited is our majority-owned subsidiary located in Hong Kong.